ARCHIVES

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Bloch Pushes PDQ Promotion To Public, But NCAB Limits It to Physicians

February 17, 1984

NRC Group Splits Over chemical Dose Testing For Carcinogenicity

March 12, 1993

Cooperative group chairman suggest changes to incentive system.

August 13, 2004

DCE Board Approves Two New Grant Programs, New Contract, Recompetitions Totaling $22 Mil.

March 9, 1990

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

April 26, 1996

NCAB May Determine Fate Of NCOG, Possibly Other Regional Groups; Simone Denies CCIRC Prejudice

May 8, 1981